牛牛AI助理已提取核心訊息
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on 02/15/2024, according to a recent filing. The shares, valued at an aggregate market value of $1,607,176, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This planned sale follows a three-month period where Kulkarni sold 70,000 shares, generating gross proceeds of $4,275,626.
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 20,000 shares of common stock on 02/15/2024, according to a recent filing. The shares, valued at an aggregate market value of $1,607,176, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This planned sale follows a three-month period where Kulkarni sold 70,000 shares, generating gross proceeds of $4,275,626.
最近的一份文件顯示，同時擔任高管兼董事的CRISPR Therapeutics高管薩瑪斯·庫爾卡尼定於2024年2月15日出售2萬股普通股。這些股票的總市值爲1,607,176美元，於當天通過行使股票期權收購，該交易涉及向發行人支付現金。此次計劃出售是在庫爾卡尼在三個月內出售了7萬股股票之後進行的，總收益爲4,275,626美元。
最近的一份文件顯示，同時擔任高管兼董事的CRISPR Therapeutics高管薩瑪斯·庫爾卡尼定於2024年2月15日出售2萬股普通股。這些股票的總市值爲1,607,176美元，於當天通過行使股票期權收購，該交易涉及向發行人支付現金。此次計劃出售是在庫爾卡尼在三個月內出售了7萬股股票之後進行的，總收益爲4,275,626美元。
有用
沒用